Brief: JCR Pharmaceuticals - Received Marketing Authorization In UAE For Izcargo, Therapy For Hunter Syndrome
21/07/2026 05:32
BRIEF-JCR Pharmaceuticals - Received Marketing Authorization In UAE For Izcargo, Therapy For Hunter Syndrome July 21 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T:
RECEIVED MARKETING AUTHORIZATION IN UNITED ARAB EMIRATES FOR IZCARGO, THERAPY FOR HUNTER SYNDROME
Source text: ID:nTSsu91b0d
Further company coverage: 4552.T
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results